Hims & Hers Health, Inc. (HIMS)
Hims & Hers Health, Inc. (HIMS) Laps the Stock Market: Here's Why
In the most recent trading session, Hims & Hers Health, Inc. (HIMS) closed at $23.11, indicating a +1.18% shift from the previous trading day.
2 Incredibly Cheap Growth Stocks to Buy Now
These companies are on different growth trajectories, but each has something to offer long-term investors. Hims & Hers is increasing subscribers and revenue rapidly, while profitability is expanding.
Hims & Hers Health, Inc. (HIMS) Is a Trending Stock: Facts to Know Before Betting on It
Hims & Hers Health (HIMS) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Jim Cramer on Hims & Hers Health stock: 'I bet the business stays strong'
CNBC's Jim Cramer gave his take on the Hims & Hers Health, a digital health and wellness platform, saying it might be worth opening a position in the stock now that it's pulled back somewhat from its highs. Hims & Hers offers telehealth services and direct-to-consumer treatments for erectile dysfunction and hair loss, and it just announced it would start selling compounded GLP-1 weight loss injections.
Are Medical Stocks Lagging Hims & Hers Health (HIMS) This Year?
Here is how Hims & Hers Health, Inc. (HIMS) and Novo Nordisk (NVO) have performed compared to their sector so far this year.
Hims & Hers (HIMS) Gains 37.7% in Three Months: What's Next?
Hims & Hers (HIMS) is enhancing its offerings and expanding the breadth of health and wellness products and services. However, macro challenges are likely to hurt its performance.
Is Hims & Hers Stock a Buy After Short Report?
There are valid points in the short report, but it may present a buying opportunity for long-term investors.
HIMS Stock Tumbles: Here's Why It's a Buy Right Now
Hims & Hers Health is a high growth, healthcare startup stepping into the GLP-1 space.
Hims & Hers Stock Drops 12.8% After Short Report
A short report was published that makes a case against Hims & Hers' new GLP-1 product. The report was put out by a media organization with ties to a fund that is also a short-seller of the stock.
Short Seller Hunterbrook Slams Hims & Hers (HIMS) Stock in New Report
Hims & Hers Health (NYSE: HIMS ) stock is taking a tumble after Hunterbrook Media released a short report on the telehealth company. Hunterbrook operates an interesting business model, as it publishes research on stocks through Hunterbrook Media while sometimes taking a position in the same stock through its hedge fund affiliate, Hunterbrook Capital.
Hims & Hers Health, Inc. (HIMS) Flat As Market Sinks: What You Should Know
In the latest trading session, Hims & Hers Health, Inc. (HIMS) closed at $22.15, marking no change from the previous day.
Should You Buy Hims & Hers Health Stock Right Now?
The telehealth company is offering innovative products at lower prices.
